An USPTO patent has been granted to Regulus Therapeutics Inc., a biopharmaceutical company which leads the discovery and development of innovative medicines targeting microRNAs (miR) on 12 November 2015. The patent is related to Regulus' most advanced two microRNA therapeutics, RG-101(GalNAc-conjugated anti-miR-122 being developed to treat HCV...